Deal Details
Convertible Notes Offering
Summary
Baird served as a co-manager on the offering
About
Exact Sciences Corporation (“Exact” or the “Company”) (NASDAQ: EXAS) recently completed a convertible notes offering of $747.5 million 0.375% Convertible Senior Notes due 2027, which includes $97.5 million aggregate principal amount of notes solely to cover over-allotments. Exact intends to use the net proceeds received from this offering to exchange the 2025 notes, and the remaining proceeds for general corporate and working capital purposes.Exact is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The Company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard® for the early detection of colorectal cancer and pre-cancer, and are working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer diagnostics. Exact is headquartered in Madison, Wisconsin.
CONTACT US TO LEARN MORE
- Date
- March 2019
- Company
- Exact Sciences Corporation
- Transaction
- M&A
- Sectors
- Healthcare
- Target Geography
- North America
Share
